PET/CT in patients with hepatocellular carcinoma using [ 18F]fluorocholine: Preliminary comparison with [18F]FDG PET/CT

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 11, 2006, Pages 1285-1289

  Talbot, Jean Noël ^a   Gutman, Fabrice ^a   Fartoux, Laetitia ^b   Grange, Jean Didier ^a   Ganne, Nathalie ^c   Kerrou, Khaldoun ^a   Grahek, Dany ^a   Montravers, Françoise ^a   Poupon, Raoul ^b   Rosmorduc, Olivier ^b  

^a HÔPITAL TENON   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c HÔPITAL JEAN VERDIER   (France)

Author keywords

Fluorocholine (18F); Hepatology; Oncology; PET; PET CT

Indexed keywords

ACETIC ACID C 11; CHOLINE DERIVATIVE; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG UPTAKE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LIPID METABOLISM; LIVER BIOPSY; LIVER CELL CARCINOMA; MALE; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; SIGNAL NOISE RATIO;

CARCINOMA, HEPATOCELLULAR; CHOLINE; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33750294785     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0164-9     Document Type: Article

References (20)

1. Zornig C, Broelsch CE. Impact of staging on the treatment of hepatocellular carcinoma. Endoscopy 1993;25:138-142
2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699
3. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133:510-515, discussion 515-516
4. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32:792-797
5. Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992;33:333-339
6. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999;94:3314-3319
7. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003;44:213-221
8. Li CW, Kuo YC, Chen CY, Kuo YT, Chiu YY, She FO, et al. Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3 T. Magn Reson Med 2005;53:770-776
9. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236
10. Rush C, Stern J. Gallium-67 SPECT imaging in hepatocellular carcinoma. Clin Nucl Med 1988;13:535-537
11. Serafini AN, Jeffers LJ, Reddy KR, Heiba S, Schiff ER. Early recognition of recurrent hepatocellular carcinoma utilizing gallium-67 citrate scintigraphy. J Nucl Med 1988;29:712-716
12. Chang CS, Yang SS, Yeh HZ, Kao CH, Chen GH. Tc-99m MIBI liver imaging for hepatocellular carcinoma: correlation with P-glycoprotein-multidrug-resistance gene expression. Hepatogastroenterology 2004;51:211-214
13. Shreve P, Chiao PC, Humes HD, Schwaiger M, Gross MD. Carbon-11-acetate PET imaging in renal disease. J Nucl Med 1995;36:1595-1601
14. Shreve PD, Gross MD. Imaging of the pancreas and related diseases with PET carbon-11-acetate. J Nucl Med 1997;38:1305-10.
15. Yoshimoto M, Waki A, Yonekura Y, Sadato N, Murata T, Omata N, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 2001;28:117-122
16. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001;61:110-117
17. 18F-fluorocholine: a new oncologic PET tracer. J Nucl Med 2001;42:1815-1817
18. Kwee SA, Coel MN, Lim J, Ko JP. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol 2005;173:252-255
19. Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005;235:623-628
20. Ruiz-Cabello J, Cohen JS. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed 1992;5:226-233